These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 10656205

  • 1. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease.
    von Tirpitz C, Klaus J, Brückel J, Rieber A, Scholer A, Adler G, Böhm BO, Reinshagen M.
    Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):19-24. PubMed ID: 10656205
    [Abstract] [Full Text] [Related]

  • 2. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
    von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M.
    Aliment Pharmacol Ther; 2003 Mar 15; 17(6):807-16. PubMed ID: 12641503
    [Abstract] [Full Text] [Related]

  • 3. Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
    Klaus J, Reinshagen M, Herdt K, Adler G, von Boyen GB, von Tirpitz C.
    J Gastrointestin Liver Dis; 2011 Jun 15; 20(2):141-8. PubMed ID: 21725510
    [Abstract] [Full Text] [Related]

  • 4. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
    Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, von Boyen GB, von Tirpitz C.
    World J Gastroenterol; 2011 Jan 21; 17(3):334-42. PubMed ID: 21253392
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
    Clin Gastroenterol Hepatol; 2005 Feb 21; 3(2):122-32. PubMed ID: 15704046
    [Abstract] [Full Text] [Related]

  • 6. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep 21; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 7. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug 21; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 8. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
    Abitbol V, Mary JY, Roux C, Soulé JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S, Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Aliment Pharmacol Ther; 2002 May 21; 16(5):919-27. PubMed ID: 11966500
    [Abstract] [Full Text] [Related]

  • 9. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?
    Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW.
    Gut; 2001 Apr 21; 48(4):473-7. PubMed ID: 11247890
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
    Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP.
    Aliment Pharmacol Ther; 2003 Dec 21; 18(11-12):1121-7. PubMed ID: 14653832
    [Abstract] [Full Text] [Related]

  • 11. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug 21; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 12. Sodium fluoride prevents bone loss in primary biliary cirrhosis.
    Guañabens N, Parés A, del Rio L, Roca M, Gómez R, Muñoz J, Rodés J.
    J Hepatol; 1992 Jul 21; 15(3):345-9. PubMed ID: 1447501
    [Abstract] [Full Text] [Related]

  • 13. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation.
    Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A.
    Eur J Gastroenterol Hepatol; 1995 Jul 21; 7(7):609-14. PubMed ID: 8590154
    [Abstract] [Full Text] [Related]

  • 14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 21; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 15. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
    Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B.
    J Bone Miner Res; 1990 Mar 21; 5 Suppl 1():S5-26. PubMed ID: 2187327
    [Abstract] [Full Text] [Related]

  • 16. [Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors].
    Von Tirpitz C, Pischulti G, Klaus J, Rieber A, Brückel J, Böhm BO, Adler G, Reinshagen M.
    Z Gastroenterol; 1999 Jan 21; 37(1):5-12. PubMed ID: 10091278
    [Abstract] [Full Text] [Related]

  • 17. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis).
    Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, Ziegler R.
    Exp Clin Endocrinol; 1994 Jan 21; 102(1):44-9. PubMed ID: 8005208
    [Abstract] [Full Text] [Related]

  • 18. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 21; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, Stuckey BG, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K.
    Osteoporos Int; 2002 Jun 21; 13(2):158-70. PubMed ID: 11908491
    [Abstract] [Full Text] [Related]

  • 20. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
    Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ.
    N Engl J Med; 1990 Mar 22; 322(12):802-9. PubMed ID: 2407957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.